Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
July 15, 2019 at 08:00 am EDT
Share
Daré Bioscience, Inc. announced that William H. Rastetter, Ph.D., a current member of its Board of Directors, was appointed Chairman of its Board of Directors effective July 11, 2019. Dr. Rastetter has been involved in the biotech industry for more than 37 years in various capacities, including serving as the chief executive and chairman of the board of numerous companies, and being an advisor to investment banking and venture capital focused on the industry. Among his other successful accomplishments, Dr. Rastetter served as the Chairman and CEO of IDEC Pharmaceuticals Corp. and was instrumental in leading the multi-billion dollar merger of equals between IDEC and Biogen, Inc. He was Chairman of Illumina Inc. from 2005 to 2016 and helped maintain the company’s independence in the face of hostile takeover interests. Dr. Rastetter was also Chairman and cofounder of Receptos, Inc., which was acquired by Celgene Corporation in 2015.
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
DARÉ BIOSCIENCE, INC. 
